

Global Long-term Treatment Drugs for Obesity Market Growth 2026-2032

<https://marketpublishers.com/r/GE155EEBEAC5EN.html>

Date: September 2026

Pages: 98

Price: US\$ 3,660.00 (Single User License)

ID: GE155EEBEAC5EN

Abstracts

The global Long-term Treatment Drugs for Obesity market size is predicted to grow from US\$ million in 2025 to US\$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.

Long-acting weight loss drugs, also known as extended-release or sustained-release weight loss medications, are pharmaceuticals designed to help individuals manage their weight by reducing appetite, increasing feelings of fullness, or altering the body's metabolism over an extended period. These drugs are formulated to provide more sustained effects, allowing for less frequent dosing. It's essential to note that these medications are typically prescribed under the guidance of a healthcare professional and are intended for use as part of a comprehensive weight management program.

The market for long-term treatment drugs for obesity is gradually emerging in response to the escalating global obesity epidemic. With increasing awareness of health, there is a growing demand for drugs for the long-term treatment of obesity. The market size is expanding, and sales are steadily increasing year by year. These drugs are primarily used to assist patients in weight loss, improve metabolism, and reduce the risk of obesity-related diseases. Future development trends indicate that the market for long-term treatment drugs for obesity will continue to benefit from the global focus on obesity, with innovation in research and development and market promotion being key drivers of industry growth.

LP Information, Inc. (LPI) ' newest research report, the "Long-term Treatment Drugs for Obesity Industry Forecast" looks at past sales and reviews total world Long-term Treatment Drugs for Obesity sales in 2025, providing a comprehensive analysis by region and market sector of projected Long-term Treatment Drugs for Obesity sales for

2026 through 2032. With Long-term Treatment Drugs for Obesity sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Long-term Treatment Drugs for Obesity industry.

This Insight Report provides a comprehensive analysis of the global Long-term Treatment Drugs for Obesity landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Long-term Treatment Drugs for Obesity portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Long-term Treatment Drugs for Obesity market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Long-term Treatment Drugs for Obesity and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Long-term Treatment Drugs for Obesity.

This report presents a comprehensive overview, market shares, and growth opportunities of Long-term Treatment Drugs for Obesity market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Orlistat

Semaglutide

Liraglutide

Other

Segmentation by Application:

Hospital

Clinic

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Novo Nordisk

Roche

GSK

Vivus

Arena

Orexigen

Key Questions Addressed in this Report

What is the 10-year outlook for the global Long-term Treatment Drugs for Obesity market?

What factors are driving Long-term Treatment Drugs for Obesity market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Long-term Treatment Drugs for Obesity market opportunities vary by end market size?

How does Long-term Treatment Drugs for Obesity break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Long-term Treatment Drugs for Obesity Annual Sales 2021-2032
 - 2.1.2 World Current & Future Analysis for Long-term Treatment Drugs for Obesity by Geographic Region, 2021, 2025 & 2032
 - 2.1.3 World Current & Future Analysis for Long-term Treatment Drugs for Obesity by Country/Region, 2021, 2025 & 2032
- 2.2 Long-term Treatment Drugs for Obesity Segment by Type
 - 2.2.1 Orlistat
 - 2.2.2 Semaglutide
 - 2.2.3 Liraglutide
 - 2.2.4 Other
 - 2.2.5 Long-term Treatment Drugs for Obesity Sales by Type
 - 2.2.5.1 Global Long-term Treatment Drugs for Obesity Sales Market Share by Type (2021-2026)
 - 2.2.5.2 Global Long-term Treatment Drugs for Obesity Revenue and Market Share by Type (2021-2026)
 - 2.2.5.3 Global Long-term Treatment Drugs for Obesity Sale Price by Type (2021-2026)
- 2.3 Long-term Treatment Drugs for Obesity Segment by Application
 - 2.3.1 Hospital
 - 2.3.2 Clinic
 - 2.3.3 Other
 - 2.3.4 Long-term Treatment Drugs for Obesity Sales by Application
 - 2.3.4.1 Global Long-term Treatment Drugs for Obesity Sale Market Share by Application (2021-2026)

2.3.4.2 Global Long-term Treatment Drugs for Obesity Revenue and Market Share by Application (2021-2026)

2.3.4.3 Global Long-term Treatment Drugs for Obesity Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Long-term Treatment Drugs for Obesity Breakdown Data by Company

3.1.1 Global Long-term Treatment Drugs for Obesity Annual Sales by Company (2021-2026)

3.1.2 Global Long-term Treatment Drugs for Obesity Sales Market Share by Company (2021-2026)

3.2 Global Long-term Treatment Drugs for Obesity Annual Revenue by Company (2021-2026)

3.2.1 Global Long-term Treatment Drugs for Obesity Revenue by Company (2021-2026)

3.2.2 Global Long-term Treatment Drugs for Obesity Revenue Market Share by Company (2021-2026)

3.3 Global Long-term Treatment Drugs for Obesity Sale Price by Company

3.4 Key Manufacturers Long-term Treatment Drugs for Obesity Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Long-term Treatment Drugs for Obesity Product Location Distribution

3.4.2 Players Long-term Treatment Drugs for Obesity Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR LONG-TERM TREATMENT DRUGS FOR OBESITY BY GEOGRAPHIC REGION

4.1 World Historic Long-term Treatment Drugs for Obesity Market Size by Geographic Region (2021-2026)

4.1.1 Global Long-term Treatment Drugs for Obesity Annual Sales by Geographic Region (2021-2026)

4.1.2 Global Long-term Treatment Drugs for Obesity Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic Long-term Treatment Drugs for Obesity Market Size by Country/Region (2021-2026)

4.2.1 Global Long-term Treatment Drugs for Obesity Annual Sales by Country/Region (2021-2026)

4.2.2 Global Long-term Treatment Drugs for Obesity Annual Revenue by Country/Region (2021-2026)

4.3 Americas Long-term Treatment Drugs for Obesity Sales Growth

4.4 APAC Long-term Treatment Drugs for Obesity Sales Growth

4.5 Europe Long-term Treatment Drugs for Obesity Sales Growth

4.6 Middle East & Africa Long-term Treatment Drugs for Obesity Sales Growth

5 AMERICAS

5.1 Americas Long-term Treatment Drugs for Obesity Sales by Country

5.1.1 Americas Long-term Treatment Drugs for Obesity Sales by Country (2021-2026)

5.1.2 Americas Long-term Treatment Drugs for Obesity Revenue by Country (2021-2026)

5.2 Americas Long-term Treatment Drugs for Obesity Sales by Type (2021-2026)

5.3 Americas Long-term Treatment Drugs for Obesity Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Long-term Treatment Drugs for Obesity Sales by Region

6.1.1 APAC Long-term Treatment Drugs for Obesity Sales by Region (2021-2026)

6.1.2 APAC Long-term Treatment Drugs for Obesity Revenue by Region (2021-2026)

6.2 APAC Long-term Treatment Drugs for Obesity Sales by Type (2021-2026)

6.3 APAC Long-term Treatment Drugs for Obesity Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Long-term Treatment Drugs for Obesity by Country

7.1.1 Europe Long-term Treatment Drugs for Obesity Sales by Country (2021-2026)

7.1.2 Europe Long-term Treatment Drugs for Obesity Revenue by Country (2021-2026)

7.2 Europe Long-term Treatment Drugs for Obesity Sales by Type (2021-2026)

7.3 Europe Long-term Treatment Drugs for Obesity Sales by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Long-term Treatment Drugs for Obesity by Country

8.1.1 Middle East & Africa Long-term Treatment Drugs for Obesity Sales by Country (2021-2026)

8.1.2 Middle East & Africa Long-term Treatment Drugs for Obesity Revenue by Country (2021-2026)

8.2 Middle East & Africa Long-term Treatment Drugs for Obesity Sales by Type (2021-2026)

8.3 Middle East & Africa Long-term Treatment Drugs for Obesity Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Long-term Treatment Drugs for Obesity

10.3 Manufacturing Process Analysis of Long-term Treatment Drugs for Obesity

10.4 Industry Chain Structure of Long-term Treatment Drugs for Obesity

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Long-term Treatment Drugs for Obesity Distributors

11.3 Long-term Treatment Drugs for Obesity Customer

12 WORLD FORECAST REVIEW FOR LONG-TERM TREATMENT DRUGS FOR OBESITY BY GEOGRAPHIC REGION

12.1 Global Long-term Treatment Drugs for Obesity Market Size Forecast by Region

12.1.1 Global Long-term Treatment Drugs for Obesity Forecast by Region (2027-2032)

12.1.2 Global Long-term Treatment Drugs for Obesity Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global Long-term Treatment Drugs for Obesity Forecast by Type (2027-2032)

12.7 Global Long-term Treatment Drugs for Obesity Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Novo Nordisk

13.1.1 Novo Nordisk Company Information

13.1.2 Novo Nordisk Long-term Treatment Drugs for Obesity Product Portfolios and Specifications

13.1.3 Novo Nordisk Long-term Treatment Drugs for Obesity Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 Novo Nordisk Main Business Overview

13.1.5 Novo Nordisk Latest Developments

13.2 Roche

13.2.1 Roche Company Information

13.2.2 Roche Long-term Treatment Drugs for Obesity Product Portfolios and Specifications

13.2.3 Roche Long-term Treatment Drugs for Obesity Sales, Revenue, Price and Gross Margin (2021-2026)

13.2.4 Roche Main Business Overview

13.2.5 Roche Latest Developments

13.3 GSK

13.3.1 GSK Company Information

13.3.2 GSK Long-term Treatment Drugs for Obesity Product Portfolios and Specifications

13.3.3 GSK Long-term Treatment Drugs for Obesity Sales, Revenue, Price and Gross Margin (2021-2026)

13.3.4 GSK Main Business Overview

13.3.5 GSK Latest Developments

13.4 Vivus

13.4.1 Vivus Company Information

13.4.2 Vivus Long-term Treatment Drugs for Obesity Product Portfolios and Specifications

13.4.3 Vivus Long-term Treatment Drugs for Obesity Sales, Revenue, Price and Gross Margin (2021-2026)

13.4.4 Vivus Main Business Overview

13.4.5 Vivus Latest Developments

13.5 Arena

13.5.1 Arena Company Information

13.5.2 Arena Long-term Treatment Drugs for Obesity Product Portfolios and Specifications

13.5.3 Arena Long-term Treatment Drugs for Obesity Sales, Revenue, Price and Gross Margin (2021-2026)

13.5.4 Arena Main Business Overview

13.5.5 Arena Latest Developments

13.6 Orexigen

13.6.1 Orexigen Company Information

13.6.2 Orexigen Long-term Treatment Drugs for Obesity Product Portfolios and Specifications

13.6.3 Orexigen Long-term Treatment Drugs for Obesity Sales, Revenue, Price and Gross Margin (2021-2026)

13.6.4 Orexigen Main Business Overview

13.6.5 Orexigen Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Long-term Treatment Drugs for Obesity Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Long-term Treatment Drugs for Obesity Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Orlistat

Table 4. Major Players of Semaglutide

Table 5. Major Players of Liraglutide

Table 6. Major Players of Other

Table 7. Global Long-term Treatment Drugs for Obesity Sales by Type (2021-2026) & (K Units)

Table 8. Global Long-term Treatment Drugs for Obesity Sales Market Share by Type (2021-2026)

Table 9. Global Long-term Treatment Drugs for Obesity Revenue by Type (2021-2026) & (\$ million)

Table 10. Global Long-term Treatment Drugs for Obesity Revenue Market Share by Type (2021-2026)

Table 11. Global Long-term Treatment Drugs for Obesity Sale Price by Type (2021-2026) & (US\$/Unit)

Table 12. Global Long-term Treatment Drugs for Obesity Sale by Application (2021-2026) & (K Units)

Table 13. Global Long-term Treatment Drugs for Obesity Sale Market Share by Application (2021-2026)

Table 14. Global Long-term Treatment Drugs for Obesity Revenue by Application (2021-2026) & (\$ million)

Table 15. Global Long-term Treatment Drugs for Obesity Revenue Market Share by Application (2021-2026)

Table 16. Global Long-term Treatment Drugs for Obesity Sale Price by Application (2021-2026) & (US\$/Unit)

Table 17. Global Long-term Treatment Drugs for Obesity Sales by Company (2021-2026) & (K Units)

Table 18. Global Long-term Treatment Drugs for Obesity Sales Market Share by Company (2021-2026)

Table 19. Global Long-term Treatment Drugs for Obesity Revenue by Company (2021-2026) & (\$ millions)

Table 20. Global Long-term Treatment Drugs for Obesity Revenue Market Share by

Company (2021-2026)

Table 21. Global Long-term Treatment Drugs for Obesity Sale Price by Company (2021-2026) & (US\$/Unit)

Table 22. Key Manufacturers Long-term Treatment Drugs for Obesity Producing Area Distribution and Sales Area

Table 23. Players Long-term Treatment Drugs for Obesity Products Offered

Table 24. Long-term Treatment Drugs for Obesity Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 25. New Products and Potential Entrants

Table 26. Market M&A Activity & Strategy

Table 27. Global Long-term Treatment Drugs for Obesity Sales by Geographic Region (2021-2026) & (K Units)

Table 28. Global Long-term Treatment Drugs for Obesity Sales Market Share Geographic Region (2021-2026)

Table 29. Global Long-term Treatment Drugs for Obesity Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 30. Global Long-term Treatment Drugs for Obesity Revenue Market Share by Geographic Region (2021-2026)

Table 31. Global Long-term Treatment Drugs for Obesity Sales by Country/Region (2021-2026) & (K Units)

Table 32. Global Long-term Treatment Drugs for Obesity Sales Market Share by Country/Region (2021-2026)

Table 33. Global Long-term Treatment Drugs for Obesity Revenue by Country/Region (2021-2026) & (\$ millions)

Table 34. Global Long-term Treatment Drugs for Obesity Revenue Market Share by Country/Region (2021-2026)

Table 35. Americas Long-term Treatment Drugs for Obesity Sales by Country (2021-2026) & (K Units)

Table 36. Americas Long-term Treatment Drugs for Obesity Sales Market Share by Country (2021-2026)

Table 37. Americas Long-term Treatment Drugs for Obesity Revenue by Country (2021-2026) & (\$ millions)

Table 38. Americas Long-term Treatment Drugs for Obesity Sales by Type (2021-2026) & (K Units)

Table 39. Americas Long-term Treatment Drugs for Obesity Sales by Application (2021-2026) & (K Units)

Table 40. APAC Long-term Treatment Drugs for Obesity Sales by Region (2021-2026) & (K Units)

Table 41. APAC Long-term Treatment Drugs for Obesity Sales Market Share by Region

(2021-2026)

Table 42. APAC Long-term Treatment Drugs for Obesity Revenue by Region
(2021-2026) & (\$ millions)

Table 43. APAC Long-term Treatment Drugs for Obesity Sales by Type (2021-2026) &
(K Units)

Table 44. APAC Long-term Treatment Drugs for Obesity Sales by Application
(2021-2026) & (K Units)

Table 45. Europe Long-term Treatment Drugs for Obesity Sales by Country
(2021-2026) & (K Units)

Table 46. Europe Long-term Treatment Drugs for Obesity Revenue by Country
(2021-2026) & (\$ millions)

Table 47. Europe Long-term Treatment Drugs for Obesity Sales by Type (2021-2026) &
(K Units)

Table 48. Europe Long-term Treatment Drugs for Obesity Sales by Application
(2021-2026) & (K Units)

Table 49. Middle East & Africa Long-term Treatment Drugs for Obesity Sales by
Country (2021-2026) & (K Units)

Table 50. Middle East & Africa Long-term Treatment Drugs for Obesity Revenue Market
Share by Country (2021-2026)

Table 51. Middle East & Africa Long-term Treatment Drugs for Obesity Sales by Type
(2021-2026) & (K Units)

Table 52. Middle East & Africa Long-term Treatment Drugs for Obesity Sales by
Application (2021-2026) & (K Units)

Table 53. Key Market Drivers & Growth Opportunities of Long-term Treatment Drugs for
Obesity

Table 54. Key Market Challenges & Risks of Long-term Treatment Drugs for Obesity

Table 55. Key Industry Trends of Long-term Treatment Drugs for Obesity

Table 56. Long-term Treatment Drugs for Obesity Raw Material

Table 57. Key Suppliers of Raw Materials

Table 58. Long-term Treatment Drugs for Obesity Distributors List

Table 59. Long-term Treatment Drugs for Obesity Customer List

Table 60. Global Long-term Treatment Drugs for Obesity Sales Forecast by Region
(2027-2032) & (K Units)

Table 61. Global Long-term Treatment Drugs for Obesity Revenue Forecast by Region
(2027-2032) & (\$ millions)

Table 62. Americas Long-term Treatment Drugs for Obesity Sales Forecast by Country
(2027-2032) & (K Units)

Table 63. Americas Long-term Treatment Drugs for Obesity Annual Revenue Forecast
by Country (2027-2032) & (\$ millions)

Table 64. APAC Long-term Treatment Drugs for Obesity Sales Forecast by Region (2027-2032) & (K Units)

Table 65. APAC Long-term Treatment Drugs for Obesity Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 66. Europe Long-term Treatment Drugs for Obesity Sales Forecast by Country (2027-2032) & (K Units)

Table 67. Europe Long-term Treatment Drugs for Obesity Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 68. Middle East & Africa Long-term Treatment Drugs for Obesity Sales Forecast by Country (2027-2032) & (K Units)

Table 69. Middle East & Africa Long-term Treatment Drugs for Obesity Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 70. Global Long-term Treatment Drugs for Obesity Sales Forecast by Type (2027-2032) & (K Units)

Table 71. Global Long-term Treatment Drugs for Obesity Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 72. Global Long-term Treatment Drugs for Obesity Sales Forecast by Application (2027-2032) & (K Units)

Table 73. Global Long-term Treatment Drugs for Obesity Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 74. Novo Nordisk Basic Information, Long-term Treatment Drugs for Obesity Manufacturing Base, Sales Area and Its Competitors

Table 75. Novo Nordisk Long-term Treatment Drugs for Obesity Product Portfolios and Specifications

Table 76. Novo Nordisk Long-term Treatment Drugs for Obesity Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 77. Novo Nordisk Main Business

Table 78. Novo Nordisk Latest Developments

Table 79. Roche Basic Information, Long-term Treatment Drugs for Obesity Manufacturing Base, Sales Area and Its Competitors

Table 80. Roche Long-term Treatment Drugs for Obesity Product Portfolios and Specifications

Table 81. Roche Long-term Treatment Drugs for Obesity Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 82. Roche Main Business

Table 83. Roche Latest Developments

Table 84. GSK Basic Information, Long-term Treatment Drugs for Obesity Manufacturing Base, Sales Area and Its Competitors

Table 85. GSK Long-term Treatment Drugs for Obesity Product Portfolios and

Specifications

Table 86. GSK Long-term Treatment Drugs for Obesity Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 87. GSK Main Business

Table 88. GSK Latest Developments

Table 89. Vivus Basic Information, Long-term Treatment Drugs for Obesity Manufacturing Base, Sales Area and Its Competitors

Table 90. Vivus Long-term Treatment Drugs for Obesity Product Portfolios and Specifications

Table 91. Vivus Long-term Treatment Drugs for Obesity Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 92. Vivus Main Business

Table 93. Vivus Latest Developments

Table 94. Arena Basic Information, Long-term Treatment Drugs for Obesity Manufacturing Base, Sales Area and Its Competitors

Table 95. Arena Long-term Treatment Drugs for Obesity Product Portfolios and Specifications

Table 96. Arena Long-term Treatment Drugs for Obesity Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 97. Arena Main Business

Table 98. Arena Latest Developments

Table 99. Orexigen Basic Information, Long-term Treatment Drugs for Obesity Manufacturing Base, Sales Area and Its Competitors

Table 100. Orexigen Long-term Treatment Drugs for Obesity Product Portfolios and Specifications

Table 101. Orexigen Long-term Treatment Drugs for Obesity Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 102. Orexigen Main Business

Table 103. Orexigen Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Long-term Treatment Drugs for Obesity

Figure 2. Long-term Treatment Drugs for Obesity Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Long-term Treatment Drugs for Obesity Sales Growth Rate 2021-2032 (K Units)

Figure 7. Global Long-term Treatment Drugs for Obesity Revenue Growth Rate 2021-2032 (\$ millions)

Figure 8. Long-term Treatment Drugs for Obesity Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Figure 9. Long-term Treatment Drugs for Obesity Sales Market Share by Country/Region (2025)

Figure 10. Long-term Treatment Drugs for Obesity Sales Market Share by Country/Region (2021, 2025 & 2032)

Figure 11. Product Picture of Orlistat

Figure 12. Product Picture of Semaglutide

Figure 13. Product Picture of Liraglutide

Figure 14. Product Picture of Other

Figure 15. Global Long-term Treatment Drugs for Obesity Sales Market Share by Type in 2026

Figure 16. Global Long-term Treatment Drugs for Obesity Revenue Market Share by Type (2021-2026)

Figure 17. Long-term Treatment Drugs for Obesity Consumed in Hospital

Figure 18. Global Long-term Treatment Drugs for Obesity Market: Hospital (2021-2026) & (K Units)

Figure 19. Long-term Treatment Drugs for Obesity Consumed in Clinic

Figure 20. Global Long-term Treatment Drugs for Obesity Market: Clinic (2021-2026) & (K Units)

Figure 21. Long-term Treatment Drugs for Obesity Consumed in Other

Figure 22. Global Long-term Treatment Drugs for Obesity Market: Other (2021-2026) & (K Units)

Figure 23. Global Long-term Treatment Drugs for Obesity Sale Market Share by Application (2025)

Figure 24. Global Long-term Treatment Drugs for Obesity Revenue Market Share by

Application in 2026

Figure 25. Long-term Treatment Drugs for Obesity Sales by Company in 2026 (K Units)

Figure 26. Global Long-term Treatment Drugs for Obesity Sales Market Share by Company in 2026

Figure 27. Long-term Treatment Drugs for Obesity Revenue by Company in 2026 (\$ millions)

Figure 28. Global Long-term Treatment Drugs for Obesity Revenue Market Share by Company in 2026

Figure 29. Global Long-term Treatment Drugs for Obesity Sales Market Share by Geographic Region (2021-2026)

Figure 30. Global Long-term Treatment Drugs for Obesity Revenue Market Share by Geographic Region in 2026

Figure 31. Americas Long-term Treatment Drugs for Obesity Sales 2021-2026 (K Units)

Figure 32. Americas Long-term Treatment Drugs for Obesity Revenue 2021-2026 (\$ millions)

Figure 33. APAC Long-term Treatment Drugs for Obesity Sales 2021-2026 (K Units)

Figure 34. APAC Long-term Treatment Drugs for Obesity Revenue 2021-2026 (\$ millions)

Figure 35. Europe Long-term Treatment Drugs for Obesity Sales 2021-2026 (K Units)

Figure 36. Europe Long-term Treatment Drugs for Obesity Revenue 2021-2026 (\$ millions)

Figure 37. Middle East & Africa Long-term Treatment Drugs for Obesity Sales 2021-2026 (K Units)

Figure 38. Middle East & Africa Long-term Treatment Drugs for Obesity Revenue 2021-2026 (\$ millions)

Figure 39. Americas Long-term Treatment Drugs for Obesity Sales Market Share by Country in 2026

Figure 40. Americas Long-term Treatment Drugs for Obesity Revenue Market Share by Country (2021-2026)

Figure 41. Americas Long-term Treatment Drugs for Obesity Sales Market Share by Type (2021-2026)

Figure 42. Americas Long-term Treatment Drugs for Obesity Sales Market Share by Application (2021-2026)

Figure 43. United States Long-term Treatment Drugs for Obesity Revenue Growth 2021-2026 (\$ millions)

Figure 44. Canada Long-term Treatment Drugs for Obesity Revenue Growth 2021-2026 (\$ millions)

Figure 45. Mexico Long-term Treatment Drugs for Obesity Revenue Growth 2021-2026 (\$ millions)

Figure 46. Brazil Long-term Treatment Drugs for Obesity Revenue Growth 2021-2026 (\$ millions)

Figure 47. APAC Long-term Treatment Drugs for Obesity Sales Market Share by Region in 2026

Figure 48. APAC Long-term Treatment Drugs for Obesity Revenue Market Share by Region (2021-2026)

Figure 49. APAC Long-term Treatment Drugs for Obesity Sales Market Share by Type (2021-2026)

Figure 50. APAC Long-term Treatment Drugs for Obesity Sales Market Share by Application (2021-2026)

Figure 51. China Long-term Treatment Drugs for Obesity Revenue Growth 2021-2026 (\$ millions)

Figure 52. Japan Long-term Treatment Drugs for Obesity Revenue Growth 2021-2026 (\$ millions)

Figure 53. South Korea Long-term Treatment Drugs for Obesity Revenue Growth 2021-2026 (\$ millions)

Figure 54. Southeast Asia Long-term Treatment Drugs for Obesity Revenue Growth 2021-2026 (\$ millions)

Figure 55. India Long-term Treatment Drugs for Obesity Revenue Growth 2021-2026 (\$ millions)

Figure 56. Australia Long-term Treatment Drugs for Obesity Revenue Growth 2021-2026 (\$ millions)

Figure 57. China Taiwan Long-term Treatment Drugs for Obesity Revenue Growth 2021-2026 (\$ millions)

Figure 58. Europe Long-term Treatment Drugs for Obesity Sales Market Share by Country in 2026

Figure 59. Europe Long-term Treatment Drugs for Obesity Revenue Market Share by Country (2021-2026)

Figure 60. Europe Long-term Treatment Drugs for Obesity Sales Market Share by Type (2021-2026)

Figure 61. Europe Long-term Treatment Drugs for Obesity Sales Market Share by Application (2021-2026)

Figure 62. Germany Long-term Treatment Drugs for Obesity Revenue Growth 2021-2026 (\$ millions)

Figure 63. France Long-term Treatment Drugs for Obesity Revenue Growth 2021-2026 (\$ millions)

Figure 64. UK Long-term Treatment Drugs for Obesity Revenue Growth 2021-2026 (\$ millions)

Figure 65. Italy Long-term Treatment Drugs for Obesity Revenue Growth 2021-2026 (\$

millions)

Figure 66. Russia Long-term Treatment Drugs for Obesity Revenue Growth 2021-2026 (\$ millions)

Figure 67. Middle East & Africa Long-term Treatment Drugs for Obesity Sales Market Share by Country (2021-2026)

Figure 68. Middle East & Africa Long-term Treatment Drugs for Obesity Sales Market Share by Type (2021-2026)

Figure 69. Middle East & Africa Long-term Treatment Drugs for Obesity Sales Market Share by Application (2021-2026)

Figure 70. Egypt Long-term Treatment Drugs for Obesity Revenue Growth 2021-2026 (\$ millions)

Figure 71. South Africa Long-term Treatment Drugs for Obesity Revenue Growth 2021-2026 (\$ millions)

Figure 72. Israel Long-term Treatment Drugs for Obesity Revenue Growth 2021-2026 (\$ millions)

Figure 73. Turkey Long-term Treatment Drugs for Obesity Revenue Growth 2021-2026 (\$ millions)

Figure 74. GCC Countries Long-term Treatment Drugs for Obesity Revenue Growth 2021-2026 (\$ millions)

Figure 75. Manufacturing Cost Structure Analysis of Long-term Treatment Drugs for Obesity in 2026

Figure 76. Manufacturing Process Analysis of Long-term Treatment Drugs for Obesity

Figure 77. Industry Chain Structure of Long-term Treatment Drugs for Obesity

Figure 78. Channels of Distribution

Figure 79. Global Long-term Treatment Drugs for Obesity Sales Market Forecast by Region (2027-2032)

Figure 80. Global Long-term Treatment Drugs for Obesity Revenue Market Share Forecast by Region (2027-2032)

Figure 81. Global Long-term Treatment Drugs for Obesity Sales Market Share Forecast by Type (2027-2032)

Figure 82. Global Long-term Treatment Drugs for Obesity Revenue Market Share Forecast by Type (2027-2032)

Figure 83. Global Long-term Treatment Drugs for Obesity Sales Market Share Forecast by Application (2027-2032)

Figure 84. Global Long-term Treatment Drugs for Obesity Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Long-term Treatment Drugs for Obesity Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/GE155EEBEAC5EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GE155EEBEAC5EN.html>